The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.
MK-886 inhibits the reaction [ALOX5 protein results in increased metabolism of Hydroxyeicosatetraenoic Acids metabolite]; MK-886 inhibits the reaction [Nicotine results in increased expression of ALOX5 protein] MK-886 results in decreased activity of ALOX5 protein EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]]; MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]
[MK-886 results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4; MK-886 binds to and results in decreased activity of ALOX5AP protein; MK-886 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein
MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 protein]
[MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CDH1 protein]; MK-886 inhibits the reaction [Nicotine results in decreased expression of CDH1 mRNA]
[MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CTNNB1 protein]
MK-886 inhibits the reaction [Histamine results in increased expression of CXCL8 mRNA]; MK-886 inhibits the reaction [Histamine results in increased expression of CXCL8 protein]
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein
EPHX2 gene mutant form promotes the reaction [[Lipopolysaccharides co-treated with MK-886] results in decreased abundance of 11,12-dihydroxyeicosatrienoic acid]; EPHX2 gene mutant form promotes the reaction [[Lipopolysaccharides co-treated with MK-886] results in decreased abundance of 14,15-dihydroxyeicosatrienoic acid]; EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased abundance of 5-hydroxy-6,8,11,14-eicosatetraenoic acid]]; EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]]; MK-886 promotes the reaction [EPHX2 gene mutant form results in decreased susceptibility to Lipopolysaccharides]
MK-886 inhibits the reaction [3-((O-6-deoxymannopyranosyl-1-2-O-(xylopyranosyl-1-3)arabinopyranosyl)oxy)-21-glucopyranosyloxy-20-hydroxydammar-24-en-19-al inhibits the reaction [Lipopolysaccharides results in increased activity of F3 protein]]; MK-886 inhibits the reaction [pirinixic acid inhibits the reaction [Lipopolysaccharides results in increased activity of F3 protein]]
MK-886 inhibits the reaction [Dronabinol results in increased expression of FA2H mRNA]; MK-886 promotes the reaction [Dronabinol results in increased expression of FA2H mRNA]
MK-886 inhibits the reaction [mangiferin results in increased activity of LPL protein]; MK-886 inhibits the reaction [mangiferin results in increased expression of LPL mRNA]; MK-886 inhibits the reaction [Plant Extracts results in increased activity of LPL protein]; MK-886 inhibits the reaction [Plant Extracts results in increased expression of LPL mRNA]
MK-886 binds to and results in decreased activity of LTB4R protein; MK-886 inhibits the reaction [LTB4R protein results in increased susceptibility to Formaldehyde]
MK-886 inhibits the reaction [Nicotine results in increased expression of MMP9 mRNA] MK-886 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of MMP9 protein]
MK-886 inhibits the reaction [Bezafibrate results in increased expression of PDK4 mRNA]; MK-886 inhibits the reaction [Bezafibrate results in increased expression of PDK4 protein]
[MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CDH1 protein]; [MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CTNNB1 protein]; [MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to perfluorooctanoic acid; MK-886 binds to and results in decreased activity of PPARA protein; MK-886 inhibits the reaction [Arsenic Trioxide results in increased expression of PPARA protein]; MK-886 inhibits the reaction [Bezafibrate results in increased expression of PPARA mRNA]; MK-886 inhibits the reaction [mangiferin results in increased activity of PPARA protein]; MK-886 inhibits the reaction [perfluorooctane sulfonic acid results in increased activity of PPARA protein]; MK-886 inhibits the reaction [perfluorooctanoic acid results in increased activity of PPARA protein]; MK-886 inhibits the reaction [Plant Extracts results in increased activity of PPARA protein]; MK-886 promotes the reaction [Dronabinol results in increased expression of PPARA mRNA] [MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; MK-886 binds to and results in decreased activity of PPARA protein MK-886 binds to and results in decreased activity of PPARA protein; MK-886 inhibits the reaction [perfluorooctane sulfonic acid results in increased activity of PPARA protein]; MK-886 inhibits the reaction [perfluorooctanoic acid results in increased activity of PPARA protein] MK-886 results in increased expression of PPARA mRNA
[Indomethacin co-treated with MK-886] affects the localization of PPARG protein; Indomethacin promotes the reaction [MK-886 results in increased activity of PPARG protein] MK-886 results in increased expression of PPARG mRNA MK-886 affects the localization of PPARG protein
MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate]; MK-886 promotes the reaction [SOD2 gene mutant form results in increased abundance of Lactic Acid]
[Ovalbumin co-treated with MK-886] results in increased expression of TNF protein; MK-886 inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA]; monascin inhibits the reaction [[Ovalbumin co-treated with MK-886] results in increased expression of TNF protein]
MK-886 inhibits the reaction [pirinixic acid results in increased expression of UCP2 mRNA]; MK-886 inhibits the reaction [pirinixic acid results in increased expression of UCP2 protein]
browse the term
